SKSvetlana Y. Konanykhina

Svetlana Y. Konanykhina

*This is an algorithmically generated author record based on publicly available information.

Svetlana Y. Konanykhina has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical laboratory diagnostics of immediate allergic reactions in Russia: modern diagnostic solutions

    by V. I. Butvilovskaya, O. A. Svitich, S. Yu. Konanykhina, O. A. Zasedateleva, A. V. Chudinov

    A global increase in allergic diseases is being observed worldwide, characterized not only by an increasing incidence but also by increasing severity. In recent decades, allergic diseases have become one of the most significant global challenges for healthcare systems and society. This is due to three key trends: high prevalence (allergies rank third globally after cardiovascular and oncological pathologies, and in some regions, they are the leading cause of disease), a rapidly increasing incidence (doubling every ten years), and increasing severity. Despite medical advances, more severe forms of allergic diseases lead to increased cases of temporary disability and permanent disability, which reduces patients’ quality of life. The Russian Federation faces a similar situation. Since most allergic diseases are caused by immediate reactions, timely and accurate clinical laboratory diagnostics are key to their effective treatment. Modern allergy diagnostics offer a wide range of effective methods that allow for a more precise diagnosis for each individual patient and predict the success of treatment. Allergen‑specific immunoglobulin E (sIgE) is a key player in immediate allergic reactions. Its detection underlies many diagnostic procedures. Testing is performed for both individual allergens of various types and for allergen complexes (panels). The results are presented as both the sIgE concentration and the allergic reaction class. This review examines the comparison of sIgE test results using test kits from various manufacturers used for clinical laboratory diagnosis of immediate allergic reactions in the Russian Federation.

  • Open Access

    Mapping of IgE cross-reactivity of Gly m 4, Gly m 5 and Gly m 6 soybean allergens in patients with atopic diseases

    by Pavel V. Samoylikov, G. V. Vasilyeva, S. Y. Konanykhina, A. V. Poddubikov, Конаныхина С. Ю.

    Currently, a significant portion of the food consists of multiple different ingredients. Soybean proteins have been widely used for production of these combined foodstuffs. Meanwhile, soy proteins may contain a wide range of allergens, and even, if present in small amounts, they can cause severe allergic reactions due to cross-reactivity. The aims of our study were to evaluate the prevalence of sensitization to soybean allergen components Gly m 4, Gly m 5 and Gly m 6, and to map their IgE cross-reactivity with homologous proteins of Bet v1-like proteins and cupin proteins in patients with atopic disorders. We have studied IgE’s to 112 allergenic components of plant and animal origin in blood sera from 54 patients with history of allergy, using the ImmunoCap ISAC method. The results were analyzed by means of MS Excel program using parametric statistical criteria. Results: In patients with atopic diseases, we have detected serum IgE to the rGly m 4 allergic component (5 patients out of 29; 17.24%). Frequency of sIgE detection to rGly m 5 (3 patients of 29; 10.24%) and rGly m 6 (1 patient of 29; 3.44%) was less pronounced. Cross-reactive sIgE was detected only to allergens of the Bet v1 superfamily. The strongest relationship was found between sIgE level to rGly m 4 and rBet v1 (R = 0.68; p = 0.001). Another IgE cross-reaction was found between soybean rGly m 4 and alder pollen rAln g1 (R = 0.681; p = 0.000). IgE antibodies to rGly m 4 may also cross-react with kiwi rAct d8 (R = 0.59; p = 0.001). We have also found a weak correlation between sIgE to soybean rGly m 4 and two hazelnut rCor a1 isoforms: rCor a 1.01 (R = 0.42; p = 0.023), and rCor a 1.04 (R = 0.39; p = 0.036). The IgE cross-reactivity profile of the soy allergens revealed in this study is important for improvement of testing strategy for the presence of causally significant allergens. This finding will help to avoid the development of hidden cross-reactions that trigger both oral and respiratory allergic processes in subjects with allergic pathology. Moreover, this will enable administration of optimal diets and develop technologies for development of hypoallergenic food products.


  • Open Access

    An impact of lactoferrin, serum albumin and secretory immunoglobulin A in actimicrobial activity of breast milk whey

    by Vera G. Arzumanian, Tatiana I. Kolyganova, Oxana A. Svitich, Pavel V. Samoylikov, Svetlana Y. Konanykhina, Tatiana A. Zaytseva, Vitaly V. Zverev, Зайцева Татьяна Александровна

    The contribution of the antimicrobial activity of sIgA, lactoferrin, -lactalbumin, serum albumin, and lysozyme to the total antimicrobial activity of whey was evaluated. 66 breast milk samples from healthy women aged from 23 to 45 years collected at different periods of lactation were studied. It was found that along with proceeding the lactation period, not only the total antimicrobial activity (r = 0.944) decreased, but also the activity of the low molecular weight fraction containing the sum of antimicrobial peptides (r = 0.950). The median lactoferrin level varied from 3.46 mg/ml in colostrum down to 0.94 mg/ml one year after the onset of lactation that correlated with whey activity (r = 0.616). The concentration of sIgA was peaked in the whey of colostrum (5.01 mg/ml) and significantly reduced in mature milk, remaining approximately at the same level in subsequent periods of lactation (1.0 mg/ml). Serum albumin concentration significantly decreased while proceeding through lactation period (from 5.52 to 4.68 mg/ml) and correlated with whey activity (r = 0.589). Evaluating effects of the purified -lactalbumin on C. albicans cells within the range of 520 mg/ml by spectrophotometry and microscopy showed the absence of fungicidal activity. At the same time, purified lactoferrin, IgA, lysozyme, and serum albumin demonstrated a direct fungicidal effect. The activity of the IgA preparation at a concentration relevant to the sIgA content in the whey of the first day colostrum was 50.0%, and in the whey after 12 months 31.0%; lactoferrin 26.7% and 3.4%; serum albumin 15.0% and 17.7%; lysozyme 0.1% and 1.8%. Thus, the sum of the activities of these polypeptides at concentrations typical for the first-day colostrum was 91.7%, which is comparable to the total activity of this whey 82.4%. The sum of the activities of these polypeptides, typical for 12 months of lactation, was 53.9%, and the total whey activity relevant to this period was 64.5%. Therefore, IgA and lactoferrin contribute the most significant antimicrobial activity in the whey of colostrum, whereas after 12 month-breastfeeding IgA and serum albumin become most significant.


  • Open Access

    Development of the ELISA Test System for Quantitative Determination of IgG to the Varizella zoster virus in Human Serum and Assessment of its Diagnostic Efficiency

    by L. N. Lukhverchyk, G. L. Alatortseva, L. N. Nesterenko, V. Y. Kabargina, V. V. Dotsenko, I. I. Amiantova, O. B. Vylivannaya, A. V. Sidorov, A. V. Milovanova, O. S. Oksanich, et al.

    Relevance. The introduction of Varicella vaccine prophylaxis explains the need to develop a methodology for monitoring the vaccination effectiveness and the intensity of population immunity. This problem can be solved using quantitative immunoassay methods. Aim. Development of an enzyme-linked immunosorbent assay for the concentration of class G immunoglobulins (AB) to Varicella zoster virus (VZV) determining and assessing its functional characteristics and diagnostic efficiency. Materials and methods. Recombinant antigen GE VZV. WHO International Standard for Antibodies to VZV W1044. Blood serum samples from healthy people and patients with Chickenpox and Herpes zoster, blood serum samples containing IgG antibodies to herpes simplex viruses of the first and second types, cytomegalovirus, Epstein-Barr virus. Anti-VZV ELISA (IgG) reagent kit (Euroimmun, Germany). Indirect enzyme-linked immunosorbent assay. Immunization of animals with recombinant antigen GE, isolation, and purification of specific antibodies. Conjugation of monoclonal antibodies to human IgG with antibodies to antigen GE and with horseradish peroxidase. Results. An enzyme-linked immunosorbent assay in «an indirect» format has been developed to determine the specific antibodies to VZV concentration (IU/ml) in human serum/plasma. An artificial calibrator for determining the concentration of AB-VZV had been synthesized and standardized according to the International WHO-standard W1044. The main functional characteristics of the developed enzyme-linked immunosorbent assay are determined in accordance with GOST 51352-2013. The diagnostic kit was tested on blood serum samples from children with chickenpox (n = 43), adults with Herpes zoster (n = 158), healthy individuals (n = 781). The diagnostic sensitivity of the test system was 85%, the diagnostic specificity was 87% according to the ROC analysis. The absence of cross-reactivity of the test system was shown on samples with serological markers of other herpesvirus infections (n = 94). Comparative trials of the developed test system and its commercial analog, the Anti-VZV ELISA (IgG) reagent kit, did not reveal statistically significant differences between their functional characteristics. Conclusions. The developed test system for determining of the AB-VZV concentration in human serum/plasma in terms of its functional characteristics meets the GOST requirements, is characterized by high diagnostic efficiency, can be used to monitor the effectiveness of vaccine prophylaxis and strength of population immunity, as well as to assess the immune response in chickenpox and Herpes zoster.

  • Open Access

    Antimicrobial peptides and proteins in human biological fluids

    by Asiya M. Iksanova, Vera G. Arzumanian, Svetlana Y. Konanykhina, Pavel V. Samoylikov

    Antimicrobial peptides and proteins (AMPs) are endogenous compounds that have a direct antimicrobial effect on bacteria (e.g. by disrupting bacterial membranes) as well as on fungi and viruses. AMPs are the main components of the innate immunity of living organisms and are produced by both epithelial cells (skin cells, cells of respiratory tract, intestines, urinary and genital tracts) and cells of the immune system and are secreted into secretory fluids. AMPs can also act as chemoattractants for immunocompetent cells (neutrophils, monocytes, T lymphocytes, dendritic cells) in the inflammation site and affect the antigen presenting cells by modulating adaptive T cell immune responses. The representatives of the main 15 AMP classes, that we describe in this review, are the most studied group of the large pool of these compounds. We discuss their localization, expression, and concentration in various human biofluids under normal and pathological conditions.